melanoma
Teledermoscopy Adds a Dose of Health Equity to Skin Cancer
Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as ...
APRIL 26, 2025
Pharmacists Play Important Role in Melanoma Education
Counseling survivors of melanoma on sun protection and skin health is an important role for pharmacists.
APRIL 25, 2025
Survivorship Planning for Melanoma Patients
3 Questions for Christina Davis, PharmD, Clinical Oncology Pharmacy Specialist, University of Colorado Anschutz ...
APRIL 9, 2025
Pharmacists Play Important Role in Sun Safety Education
Counseling survivors of melanoma on sun protection and skin health is an important role for pharmacists, since ...
MARCH 21, 2025
FDA Approves Opdivo Qvantig for Subcutaneous Injection
The FDA approved nivolumab plus hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb) for subcutaneous ...
DECEMBER 30, 2024
FDA Approves Tecentriq Hybreza for Subcutaneous Injection for All Adult Indications of IV Tecentriq
The FDA has approved Tecentriq Hybreza for subcutaneous injection as the intravenous formulation of Tecentriq.
SEPTEMBER 16, 2024
FDA Approves Opdivo for Adjuvant Treatment of Select Patients With Stage IIB/C Melanoma
The FDA approved nivolumab (Opdivo, Bristol Myers Squibb) for the adjuvant treatment of completely resected stage ...
OCTOBER 17, 2023
Nivolumab Plus Relatlimab Approved to Treat Metastatic Melanoma
The FDA approved a fixed-dose combination of the programmed death-1–blocking antibody nivolumab and ...
MARCH 22, 2022
Kimmtrak Takes BiTE Out of Uveal Melanoma
The FDA approved tebentafusp-tebn (Kimmtrak, Immunocore), a bispecific T-cell engager (BiTE) designed to redirect ...
MARCH 22, 2022
Pembrolizumab After Resection of Stage II Melanoma Reduces Recurrence Risk
In patients with resected stage IIB or IIC melanoma, adjuvant pembrolizumab (Keytruda, Merck) significantly reduces ...
JANUARY 11, 2022
FDA Grants New Indication for Tecentriq Plus Cotellic and Zelboraf for Advanced Melanoma
The new combination increased PFS to a median of 15.1 months compared with placebo plus cobimetinib and vemurafenib ...
AUGUST 4, 2020
Keytruda Approved for Adjuvant Rx in Melanoma Patients With Lymph Node Involvement
The FDA approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with melanoma with ...
FEBRUARY 22, 2019
